Research map: Targeted Therapies in the Management of Advanced Medullary Thyroid Cancer

Back to the article

Papers in this map

  1. Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial · Samuel A. Wells · 2011 · 1568 citations · Cited by this paper
  2. Patient-driven second opinions in oncology: a review · 2026 · Related
  3. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology · Robert I. Haddad · 2022 · 526 citations · Cited by this paper
  4. Proton-Pump Inhibitor use in combination with a CDK4/6 inhibitor: Is formulation the issue? · 2026 · Related
  5. Phase II Clinical Trial of Sorafenib in Metastatic Medullary Thyroid Cancer · Elaine T. Lam · 2010 · 377 citations · Cited by this paper
  6. Durable response to sotorasib in KRAS G12C -mutant intrahepatic cholangiocarcinoma: a case report · 2026 · Related
  7. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study · Vivek Subbiah · 2021 · 366 citations · Cited by this paper
  8. Neoadjuvant intent anti-programmed death-1 immunotherapy for cutaneous squamous cell carcinoma in patients with hematologic malignancy · 2026 · Related
  9. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations · Vivek Subbiah · 2020 · 257 citations · Cited by this paper
  10. Use of liposomal irinotecan with 5-FU and oxaliplatin (NALIRIFOX) in neoadjuvant pancreatic adenocarcinoma: NEO-Nal-IRI trial · 2026 · Related
  11. A Phase II Trial of the Multitargeted Tyrosine Kinase Inhibitor Lenvatinib (E7080) in Advanced Medullary Thyroid Cancer · Martin Jean Schlumberger · 2015 · 251 citations · Cited by this paper
  12. Renal Dysfunction in Patients with CML on Long-Term First-Line TKI Therapy: A Single-Center Analysis · 2026 · Related
  13. Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid Cancer · Julien Hadoux · 2023 · 208 citations · Cited by this paper
  14. SERENA-6 visual patient-reported outcomes & safety: camizestrant for emerging ESR1 m advanced breast cancer during first-line endocrine-basedtherapy · 2026 · Related
  15. A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes · Seungtaek Lim · 2013 · 140 citations · Cited by this paper
  16. The Role of Adjuvant Chemotherapy in Small Bowel Adenocarcinomas · 2026 · Related
  17. Current Understanding and Management of Medullary Thyroid Cancer · Madhuchhanda Roy · 2013 · 124 citations · Cited by this paper
  18. Oncofertility in Gastrointestinal (GI) Oncology – A Pan-European study of the patient perspective · 2026 · Related
  19. A Multicenter Phase 2 Trial of Pazopanib in Metastatic and Progressive Medullary Thyroid Carcinoma: MC057H · Keith Christopher Bible · 2014 · 121 citations · Cited by this paper
  20. Phase IB/II study of alpelisib combined with paclitaxel in patients with PIK3CA -altered metastatic or recurrent gastric cancer · 2026 · Related
  21. Anlotinib in Locally Advanced or Metastatic Medullary Thyroid Carcinoma: A Randomized, Double-Blind Phase IIB Trial · Dapeng Li · 2021 · 117 citations · Cited by this paper
  22. Novel Targeted Therapies for Metastatic Thyroid Cancer—A Comprehensive Review · Mohammad Al-Jundi · 2020 · 102 citations · Cited by this paper
  23. Current Guidelines for Management of Medullary Thyroid Carcinoma · Mijin Kim · 2021 · 101 citations · Cited by this paper
  24. Management of tyrosine kinase inhibitors (TKI) side effects in differentiated and medullary thyroid cancer patients · Carlo Resteghini · 2017 · 80 citations · Cited by this paper
  25. Neoadjuvant selpercatinib for advanced medullary thyroid cancer · Yelda Jozaghi · 2020 · 77 citations · Cited by this paper
  26. Clinical utility of 177 Lu‐DOTATATE PRRT in somatostatin receptor‐positive metastatic medullary carcinoma of thyroid patients with assessment of efficacy, survival analysis, prognostic variables, and toxicity · Rahul Vithalrao Parghane · 2019 · 76 citations · Cited by this paper
  27. RET kinase inhibitors for RET -altered thyroid cancers · Danica Maria Vodopivec · 2022 · 64 citations · Cited by this paper
  28. Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial · Michael Christoph Kreissl · 2020 · 63 citations · Cited by this paper
  29. Incidence and risk of hypertension associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a comprehensive network meta-analysis of 72 randomized controlled trials involving 30013 patients · Bo Liu · 2016 · 56 citations · Cited by this paper
  30. Durability of Response With Selpercatinib in Patients With RET -Activated Thyroid Cancer: Long-Term Safety and Efficacy From LIBRETTO-001 · Lori J. Wirth · 2024 · 56 citations · Cited by this paper
  31. BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET -altered tumors including RET -fusion+ NSCLC and RET -mutant MTC: Phase 1 study results. · Patrick Schöffski · 2021 · 42 citations · Cited by this paper
  32. CONUT Score: A New Tool for Predicting Prognosis in Patients with Advanced Thyroid Cancer Treated with TKI · Cristina Dalmiglio · 2022 · 36 citations · Cited by this paper
  33. A phase I study of BOS172738 in patients with advanced solid tumors with RET gene alterations including non-small cell lung cancer and medullary thyroid cancer. · Patrick Schöffski · 2019 · 31 citations · Cited by this paper
  34. Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience · Mijin Kim · 2020 · 30 citations · Cited by this paper
  35. 68Ga-DOTATATE-PET shows promise for diagnosis of recurrent or persistent medullary thyroid cancer: A systematic review · Carla Pajak · 2022 · 27 citations · Cited by this paper
  36. Signaling Pathways as Specific Pharmacologic Targets for Neuroendocrine Tumor Therapy: RET, PI3K, MEK, Growth Factors, and Notch · Yvette Carter · 2012 · 23 citations · Cited by this paper
  37. Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers · Mirella Nardo · 2023 · 23 citations · Cited by this paper
  38. Targeting RET alterations in cancer: Recent progress and future directions · Arafat Shabbir · 2022 · 22 citations · Cited by this paper
  39. Efficacy and safety of concomitant 177Lu-DOTATATE and low-dose capecitabine in advanced medullary thyroid carcinoma: a single-centre experience · Swayamjeet Satapathy · 2020 · 19 citations · Cited by this paper

Source: OpenAlex (CC0)